Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy.

Nair JR, Edwards SW, Moots RJ.

Expert Opin Biol Ther. 2012 Dec;12(12):1661-8. doi: 10.1517/14712598.2012.732062. Epub 2012 Oct 25. Review.

PMID:
23094973
2.

Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.

Guo X, Higgs BW, Bay-Jensen AC, Wu Y, Karsdal MA, Kuziora M, Godwood A, Close D, Ryan PC, Roskos LK, White WI.

Rheumatology (Oxford). 2018 Jan 1;57(1):175-184. doi: 10.1093/rheumatology/kex383.

PMID:
29069507
3.

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.

Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F.

Ann Rheum Dis. 2011 Sep;70(9):1542-9. doi: 10.1136/ard.2010.146225. Epub 2011 May 25.

4.

Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.

Ryan PC, Sleeman MA, Rebelatto M, Wang B, Lu H, Chen X, Wu CY, Hinrichs MJ, Roskos L, Towers H, McKeever K, Dixit R.

Toxicol Appl Pharmacol. 2014 Sep 1;279(2):230-9. doi: 10.1016/j.taap.2014.06.002. Epub 2014 Jun 15.

5.

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date.

Crotti C, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG.

Drug Des Devel Ther. 2017 Jan 13;11:211-223. doi: 10.2147/DDDT.S104233. eCollection 2017. Review.

6.

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators.

Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17.

7.

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.

Di Franco M, Gerardi MC, Lucchino B, Conti F.

Core Evid. 2014 Mar 12;9:41-8. doi: 10.2147/CE.S39770. eCollection 2014. Review.

8.

Targeting GM-CSF in rheumatoid arthritis.

Avci AB, Feist E, Burmester GR.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):39-44. Epub 2016 Jul 21. Review.

9.

GM-CSF as a therapeutic target in inflammatory diseases.

van Nieuwenhuijze A, Koenders M, Roeleveld D, Sleeman MA, van den Berg W, Wicks IP.

Mol Immunol. 2013 Dec;56(4):675-82. doi: 10.1016/j.molimm.2013.05.002. Epub 2013 Aug 8. Review.

PMID:
23933508
10.

Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis.

Wang B, Lau YY, Liang M, Vainshtein I, Zusmanovich M, Lu H, Magrini F, Sleeman M, Roskos L.

J Clin Pharmacol. 2012 Aug;52(8):1150-61. doi: 10.1177/0091270011412964. Epub 2011 Sep 23.

PMID:
21947370
11.

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.

Greven DE, Cohen ES, Gerlag DM, Campbell J, Woods J, Davis N, van Nieuwenhuijze A, Lewis A, Heasmen S, McCourt M, Corkill D, Dodd A, Elvin J, Statache G, Wicks IP, Anderson IK, Nash A, Sleeman MA, Tak PP.

Ann Rheum Dis. 2015 Oct;74(10):1924-30. doi: 10.1136/annrheumdis-2014-205234. Epub 2014 Jun 16.

12.

GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.

Hamilton JA.

Expert Rev Clin Immunol. 2015 Apr;11(4):457-65. doi: 10.1586/1744666X.2015.1024110. Epub 2015 Mar 8. Review.

PMID:
25748625
13.

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.

Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M.

Immunol Rev. 1995 Apr;144:195-223. Review.

PMID:
7590814
14.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
15.

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.

Arthritis Rheum. 2002 Dec;46(12):3143-50.

16.
17.

Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis.

Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, Eghobamien L, Harrison P, Sims DA, Matthews C, Wilkinson T, Monk P, Drinkwater C, Fabri L, Nash A, McCourt M, Jermutus L, Roskos L, Anderson IK, Sleeman MA.

Br J Pharmacol. 2013 Jan;168(1):200-11. doi: 10.1111/j.1476-5381.2012.02173.x.

18.

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)

Maini RN, Elliott MJ, Brennan FM, Feldmann M.

Clin Exp Immunol. 1995 Aug;101(2):207-12. Review. Erratum in: Clin Exp Immunol 1995 Nov;102(2):443.

19.

Infliximab treatment of rheumatoid arthritis and Crohn's disease.

Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH.

Ann Pharmacother. 2003 Sep;37(9):1256-65. Review.

PMID:
12921510
20.

Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.

Campbell J, Nys J, Eghobamien L, Cohen ES, Robinson MJ, Sleeman MA.

MAbs. 2016 Oct;8(7):1398-1406. Epub 2016 Aug 12.

Supplemental Content

Support Center